Anthera Pharmaceuticals Inc. (ANTH) Financials Nov 14, 2014, 3:59 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Anthera Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 18,451 17,281 80,000 331,000 353,000
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 18,451 17,281 80,000 331,000 353,000
Depreciation 18,451 17,281 80,000 331,000 353,000
Amortization of Intangibles - 0 0 0 0
Gross Income (18,451) (17,281) (80,000) (331,000) (353,000)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 11.82M 35.74M 93.06M 55.6M 27.89M
Research & Development 8.42M 29.46M 85.28M 49.22M 21.68M
Other SG&A 3.41M 6.28M 7.78M 6.38M 6.21M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 (14.07M) 0
EBIT after Unusual Expense 0 0 0 14.07M 0
Non Operating Income/Expense 0 (4.66M) 606,000 (111,000) (15,000)
Non-Operating Interest Income 23,534 - - 0 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 385,922 0 2.8M 3.35M 2.6M
Gross Interest Expense 385,922 0 2.8M 3.35M 2.6M
Interest Capitalized - 0 0 0 0
Pretax Income (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
Minority Interest Expense 0 0 0 0 0
Net Income (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
EPS (Basic) (4.56) (14.08) (20.40) (50.16) (1.69)
Basic Shares Outstanding 2.69M 2.86M 4.68M 903,176 18.27M
EPS (Diluted) (4.56) (14.08) (20.40) (50.16) (1.69)
Diluted Shares Outstanding 2.69M 2.86M 4.68M 903,176 18.27M
EBITDA (11.82M) (35.74M) (93.06M) (55.6M) (27.89M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Anthera Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 18,451 17,281 80,000 331,000 353,000
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 18,451 17,281 80,000 331,000 353,000
Depreciation 18,451 17,281 80,000 331,000 353,000
Amortization of Intangibles - 0 0 0 0
Gross Income (18,451) (17,281) (80,000) (331,000) (353,000)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 11.82M 35.74M 93.06M 55.6M 27.89M
Research & Development 8.42M 29.46M 85.28M 49.22M 21.68M
Other SG&A 3.41M 6.28M 7.78M 6.38M 6.21M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 (14.07M) 0
EBIT after Unusual Expense 0 0 0 14.07M 0
Non Operating Income/Expense 0 (4.66M) 606,000 (111,000) (15,000)
Non-Operating Interest Income 23,534 - - 0 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 385,922 0 2.8M 3.35M 2.6M
Gross Interest Expense 385,922 0 2.8M 3.35M 2.6M
Interest Capitalized - 0 0 0 0
Pretax Income (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
Minority Interest Expense 0 0 0 0 0
Net Income (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (12.2M) (40.41M) (95.34M) (45.33M) (30.86M)
EPS (Basic) (4.56) (14.08) (20.40) (50.16) (1.69)
Basic Shares Outstanding 2.69M 2.86M 4.68M 903,176 18.27M
EPS (Diluted) (4.56) (14.08) (20.40) (50.16) (1.69)
Diluted Shares Outstanding 2.69M 2.86M 4.68M 903,176 18.27M
EBITDA (11.82M) (35.74M) (93.06M) (55.6M) (27.89M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
